Pfizer Braftovi Trial Achieves 64.4% ORR in BRAF V600E Colorectal Cancer
Pfizer's Braftovi regimen extended PFS in BRAF V600E metastatic colorectal cancer trial, demonstrating statistically significant ORR increase to 64.4% versus 39.2% (OR=2.76; p=0.001) in Cohort 3 of the Phase 3 BREAKWATER study. Invesco Pharmaceuticals ETF weights Pfizer at 5.01%, suggesting the ETF could gain from these positive oncology results.
1. Positive Phase 3 BREAKWATER Clinical Data
Pfizer's Braftovi regimen combined encorafenib with cetuximab and FOLFIRI in metastatic colorectal cancer patients harboring the BRAF V600E mutation. Topline results from Cohort 3 showed an objective response rate of 64.4% versus 39.2% for standard-of-care therapy (OR=2.76; p=0.001), alongside a statistically significant improvement in progression-free survival, supporting potential regulatory submissions.
2. Implications for Invesco Pharmaceuticals ETF
Pfizer represents 5.01% of the Invesco Pharmaceuticals ETF (PJP). These robust oncology results may drive positive sentiment toward Pfizer and its sector peers, potentially attracting inflows and lifting the ETF’s performance.